T. Rowe Price Associates
STLN

T. Rowe Price Associates’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

T. Rowe Price Associates’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$149K Buy
48,271
+10,269
+27% +$31.5K ﹤0.01% 2915
2025
Q4 		$136K Buy
38,002
+8,238
+28% +$30.6K ﹤0.01% 2904
2025
Q3 		$104K Hold
29,764
– – ﹤0.01% 2914
2025
Q2 		$62K Buy
+29,764
New +$74.4K ﹤0.01% 2976

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates's STLN Position: Q1 2026 in Review

T. Rowe Price Associates increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 27% in Q1 2026, buying an estimated $31.5K and bringing the position to 48,271 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #2915.

T. Rowe Price Associates first reported a position in STLN in Q2 2025 and has held it in 4 quarters since. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • T. Rowe Price Associates held 48,271 shares of Starling Oncology Institute, Inc. Common Stock worth $149K as of Q1 2026.
  • T. Rowe Price Associates bought 10,269 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $31.5K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2915 holding.
  • T. Rowe Price Associates first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2025 and has held it in 4 quarters since.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.